ACM
SYRS

ACT Capital Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

ACT Capital Management’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$23K Sell
3,499
-1
-0% -$8 0.03% 66
2022
Q2 		$34K Hold
3,500
– – 0.05% 70
2022
Q1 		$42K Buy
3,500
+1,350
+63% +$24.1K 0.04% 78
2021
Q4 		$70K Sell
2,150
-3,100
-59% -$126K 0.05% 84
2021
Q3 		$235K Hold
5,250
– – 0.12% 79
2021
Q2 		$287K Buy
+5,250
New +$311K 0.15% 78

Other funds holding SYRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

ACT Capital Management's SYRS Position: Q3 2022 in Review

ACT Capital Management reduced its Syros Pharmaceuticals, Inc. Common Stock (SYRS) stake by 0.03% in Q3 2022, selling an estimated $8 and leaving 3,499 shares worth $23K. The position accounts for 0.03% of the portfolio, ranked #66.

ACT Capital Management first reported a position in SYRS in Q2 2021 and has held it in 6 quarters since. The position peaked at $287K in Q2 2021. 53 funds tracked by Wall St. Rank hold SYRS as of Q3 2022.

  • ACT Capital Management held 3,499 shares of Syros Pharmaceuticals, Inc. Common Stock worth $23K as of Q3 2022.
  • ACT Capital Management sold 1 Syros Pharmaceuticals, Inc. Common Stock share in Q3 2022, an estimated $8.
  • Syros Pharmaceuticals, Inc. Common Stock made up 0.03% of ACT Capital Management's portfolio in Q3 2022, its #66 holding.
  • ACT Capital Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q2 2021 and has held it in 6 quarters since.
  • ACT Capital Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $287K in Q2 2021.
  • 53 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q3 2022.

Based on ACT Capital Management's 13F filing for Q3 2022, filed 3 Nov 2022.